Passing 340B drug discounts to patients with COPD so they can buy inhalers at a much lower cost yielded positive outcomes both for the patients and the hospitals that serve them, new research shows.
Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings